Compare Aurobindo Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SUN PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SUN PHARMA AUROBINDO PHARMA/
SUN PHARMA
 
P/E (TTM) x 19.8 87.6 22.6% View Chart
P/BV x 4.3 3.7 114.6% View Chart
Dividend Yield % 0.2 0.6 43.2%  

Financials

 AUROBINDO PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
SUN PHARMA
Mar-20
AUROBINDO PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs830484 171.5%   
Low Rs527315 167.2%   
Sales per share (Unadj.) Rs333.9136.9 244.0%  
Earnings per share (Unadj.) Rs40.417.5 231.3%  
Cash flow per share (Unadj.) Rs51.826.0 199.0%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Dividend yield (eoy) %0.41.0 36.8%  
Book value per share (Unadj.) Rs237.1188.7 125.7%  
Shares outstanding (eoy) m585.912,399.26 24.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.02.9 69.6%   
Avg P/E ratio x16.822.9 73.4%  
P/CF ratio (eoy) x13.115.4 85.3%  
Price / Book Value ratio x2.92.1 135.1%  
Dividend payout %6.222.9 27.0%   
Avg Mkt Cap Rs m397,569958,864 41.5%   
No. of employees `00017.917.8 100.5%   
Total wages/salary Rs m25,84963,624 40.6%   
Avg. sales/employee Rs Th10,956.918,490.6 59.3%   
Avg. wages/employee Rs Th1,447.73,582.6 40.4%   
Avg. net profit/employee Rs Th1,324.32,357.6 56.2%   
INCOME DATA
Net Sales Rs m195,636328,375 59.6%  
Other income Rs m1,5536,360 24.4%   
Total revenues Rs m197,189334,735 58.9%   
Gross profit Rs m39,51969,898 56.5%  
Depreciation Rs m6,68020,528 32.5%   
Interest Rs m2,6263,027 86.7%   
Profit before tax Rs m31,76752,702 60.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-2,606 33.8%   
Tax Rs m7,2698,228 88.3%   
Profit after tax Rs m23,64541,868 56.5%  
Gross profit margin %20.221.3 94.9%  
Effective tax rate %22.915.6 146.6%   
Net profit margin %12.112.8 94.8%  
BALANCE SHEET DATA
Current assets Rs m153,645316,542 48.5%   
Current liabilities Rs m120,429157,064 76.7%   
Net working cap to sales %17.048.6 35.0%  
Current ratio x1.32.0 63.3%  
Inventory Days Days13588 154.4%  
Debtors Days Days64105 60.8%  
Net fixed assets Rs m103,909243,102 42.7%   
Share capital Rs m5862,399 24.4%   
"Free" reserves Rs m138,322450,245 30.7%   
Net worth Rs m138,908452,645 30.7%   
Long term debt Rs m1,80020,289 8.9%   
Total assets Rs m264,544682,525 38.8%  
Interest coverage x13.118.4 71.1%   
Debt to equity ratio x00 28.9%  
Sales to assets ratio x0.70.5 153.7%   
Return on assets %9.96.6 151.0%  
Return on equity %17.09.2 184.0%  
Return on capital %23.811.2 212.2%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31674,219 131.1%   
Fx outflow Rs m40,58927,964 145.1%   
Net fx Rs m56,72746,255 122.6%   
CASH FLOW
From Operations Rs m16,22065,548 24.7%  
From Investments Rs m-28,768-25,888 111.1%  
From Financial Activity Rs m19,191-57,151 -33.6%  
Net Cashflow Rs m6,656-13,857 -48.0%  

Share Holding

Indian Promoters % 54.1 63.7 84.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.1 155.0%  
FIIs % 27.7 23.0 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.3 122.9%  
Shareholders   69,601 133,026 52.3%  
Pledged promoter(s) holding % 8.6 0.5 1,615.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA  PFIZER  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 12, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS